AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms

Blood

Volumn 114, Issue 25, 2009, Pages 5201-5205

  Ding, Ye ^a   Harada, Yuka ^a   Imagawa, Jun ^a   Kimura, Akiro ^a   Harada, Hironori ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX1; CD34 ANTIGEN; GREEN FLUORESCENT PROTEIN; RUNX1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CD34 SELECTION; CELL PROLIFERATION; CELL RENEWAL; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; LEUKEMIA; LEUKEMIC TRANSFORMATION; MALE; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; PRIORITY JOURNAL; CELL CULTURE; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROVIRUS;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOBLOTTING; LEUKEMIA; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; RETROVIRIDAE; TRANSFECTION;

EID: 73949129831     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-223982     Document Type: Article

References (20)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-1148.
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17): 1779-1790.
3. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6): 2162-2168.
4. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
5. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670.
6. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-276.
7. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977.
8. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer. 1995;75(2):471-477.
9. Mavrogianni D, Viniou N, Michali E, et al. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. Int J Hematol. 2002;75(4):394-400.
10. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4):417-421.
11. Swolin B, Rodjer S, Westin J. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Ann Hematol. 2008; 87(6):467-474.
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7): 2292-2302.
13. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103(6): 2316-2324.
14. Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia. 2006;20(4):635-644.
15. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008;111(8):4297-4308.
16. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006; 108(10):3548-3555.
17. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375-379.
18. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101(2):673-680.
19. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240-248.
20. Cammenga J, Niebuhr B, Horn S, et al. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation. Cancer Res. 2007; 67(2):537-545.